Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Emerg Microbes Infect. 2023 Dec;12(2):2256416. doi: 10.1080/22221751.2023.2256416. Epub 2023 Sep 6.
The emergence of novel betacoronaviruses has posed significant financial and human health burdens, necessitating the development of appropriate tools to combat future outbreaks. In this study, we have characterized a human cell line, IGROV-1, as a robust tool to detect, propagate, and titrate betacoronaviruses SARS-CoV-2 and HCoV-OC43. IGROV-1 cells can be used for serological assays, antiviral drug testing, and isolating SARS-CoV-2 variants from patient samples. Using time-course transcriptomics, we confirmed that IGROV-1 cells exhibit a robust innate immune response upon SARS-CoV-2 infection, recapitulating the response previously observed in primary human nasal epithelial cells. We performed genome-wide CRISPR knockout genetic screens in IGROV-1 cells and identified Aryl hydrocarbon receptor (AHR) as a critical host dependency factor for both SARS-CoV-2 and HCoV-OC43. Using DiMNF, a small molecule inhibitor of AHR, we observed that the drug selectively inhibits HCoV-OC43 infection but not SARS-CoV-2. Transcriptomic analysis in primary normal human bronchial epithelial cells revealed that DiMNF blocks HCoV-OC43 infection via basal activation of innate immune responses. Our findings highlight the potential of IGROV-1 cells as a valuable diagnostic and research tool to combat betacoronavirus diseases.
新型贝塔冠状病毒的出现给金融和人类健康带来了巨大的负担,因此需要开发适当的工具来应对未来的疫情爆发。在这项研究中,我们将人源细胞系 IGROV-1 鉴定为一种强大的工具,可用于检测、繁殖和滴定贝塔冠状病毒 SARS-CoV-2 和 HCoV-OC43。IGROV-1 细胞可用于血清学检测、抗病毒药物测试以及从患者样本中分离 SARS-CoV-2 变异株。通过时间进程转录组学分析,我们证实 IGROV-1 细胞在感染 SARS-CoV-2 后会产生强烈的固有免疫反应,重现了先前在原代人鼻上皮细胞中观察到的反应。我们在 IGROV-1 细胞中进行了全基因组 CRISPR 敲除遗传筛选,发现芳香烃受体(AHR)是 SARS-CoV-2 和 HCoV-OC43 的关键宿主依赖性因子。使用小分子 AHR 抑制剂 DiMNF,我们发现该药物选择性抑制 HCoV-OC43 感染,但不抑制 SARS-CoV-2。对原代正常人支气管上皮细胞的转录组分析表明,DiMNF 通过固有免疫反应的基础激活来阻断 HCoV-OC43 感染。我们的研究结果强调了 IGROV-1 细胞作为对抗贝塔冠状病毒病的有价值的诊断和研究工具的潜力。